Mutations in RNA-binding proteins localized in ribonucleoprotein (RNP) granules, such as hnRNP A1 and TDP-43, promote aberrant protein aggregations, which are pathological hallmarks in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Protein posttranslational modifications (PTMs) are known to regulate RNP granules. In this study, we investigate the function of PARylation, an important PTM involved in DNA damage repair and cell death, in RNP-related neurodegeneration. We reveal that PARylation levels are a major regulator of the dynamic assembly-disassembly of RNP granules, and the disease-related RNPs such as hnRNP A1 and TDP-43 can both be PARylated and bind to PARylated proteins. We further identify the PARylation site of hnRNP A1 at K298, which controls the cytoplasmic translocation of hnRNP A1 in response to stress, as well as the PAR-binding motif (PBM) of hnRNP A1, which is required for the delivery and association of hnRNP A1 to stress granules. Moreover, we show that PAR not only dramatically enhances the liquid-liquid phase separation of hnRNP A1, but also promotes the co-phase separation of hnRNP A1 and TDP-43 in vitro and their interaction in vivo. Finally, we establish that both genetic and pharmacological inhibition of PARP mitigates hnRNP A1 and TDP-43-mediated neurotoxicity in cell and Drosophila models of ALS. Together, our findings indicate a novel and crucial role of PARylation in regulating the assembly and the dynamics of RNP granules, and dysregulation of PARylation may contribute to ALS disease pathogenesis. translational repression and mRNA cleavage (Gagné et al., 2008; Kotova et al., 2009; Leung et al., 2011) .
INTRODUCTION
Eukaryotic genomes encode a large number of RNA-binding proteins that can associate with RNAs to form ribonucleoprotein (RNP) complexes. RNPs contain conserved RNA binding domain(s) and protein-protein interaction domain(s). They are presented in both nucleus and cytoplasm, where they play a major role in RNA homeostasis including RNA processing, transport and turnover (Anko and Neugebauer, 2012; Lunde et al., 2007; Muller-McNicoll and Neugebauer, 2013) . RNPs can form granules by liquid-liquid phase separation (LLPS), and aberrant RNP granules enriched of irreversible amyloid fibrils and aggregations can lead to the pathogenesis of human neurodegeneration diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (Lin et al., 2015) . Posttranslational modifications (PTMs) such as phosphorylation, ubiquitination and acetylation are known to regulate the assembly and function of RNP granules (Brady et al., 2011；Cohen et al., 2015；Dammer et al., 2012 Li et al., 2017) . Recently, methylation and phosphorylation are reported to modulate phase transition of hnRNPA2 and FUS (Hofweber et al., 2018; Qamar et al., 2018; Ryan et al., 2018; Luo et al., 2018) . However, the function of other important PTMs in regulating LLPS and RNP granules remains to be explored.
Poly(ADP-ribosyl)ation (PARylation) is a reversible PTM process by which poly(ADP-ribose) (PAR) polymerases (PARPs) add ADP-ribose (ADPr) units to the Glu, Asp, Lys, Arg or Ser residue of a protein (Martello et al., 2016; Zhang et al., 2013) whereas enzymes such as PAR glycohydrolase (PARG) remove them (Niere et al., 2012; Slade et al., 2011) . The opposing effects of PARPs and PARG in regulating protein PARylation play an important role in a variety of cellular functions, including chromatin remodeling, DNA repair, transcription regulation and cell death (Ahel et al., 2008; Andrabi et al., 2006; Frizzell et al., 2009; Singh et al., 2017) .
Dysregulation in PARylation is therefore involved in various disease conditions such as cancer, neurodegeneration, oxidative stress, neural injury, and regeneration (Deng, 2009; Hanai et al., 2004; Martire et al., 2015; Brochier et al., 2015) . Interestingly, PAR as well as some PARPs and PARG are found in cytoplasmic stress granules (SG) and may regulate microRNA-mediated Since PARylation levels affected the dynamics of the RNP granules containing TDP-43 and hnRNP A1, we examined whether these proteins were PARylated or associated with PAR in cells. HA-tagged TDP-43 or Flag-tagged hnRNP A1 was expressed and immunoprecipitated from HeLa cells with anti-HA or anti-Flag, and then examined by Western blotting with a pan-PAR antibody (anti-PAR) that recognizes both mono-ADPr and poly-ADPr. Although there were proteins co-immunoprecipitated with TDP-43 that were immunoblotted positively with Page 6 of 39 anti-PAR, we did not detect obvious PARylation of TDP-43 per ser ( Fig. 2A) . To boost the PARP1 activity in cells, we treated the cells with H 2 O 2 (500 µM, 10 min) to induce PARP1 activation (Martello et al., 2016) , which markedly increased the PARylation levels of hnRNP A1 (Fig. 2B ). However, no PARylation of TDP-43 was detected even under this condition.
Nevertheless, this result did not exclude the possibility that PARylation of TDP-43 in cells occurred at a very low level that was below our detection sensitivity. In contrast, hnRNP A1 immunoprecipitated from HeLa cells showed robust stead-state and induced levels of PARylation. In addition, there were multiple PAR + bands of proteins of higher molecular weights that were co-immunoprecipitated with hnRNP A1, especially when treated with H 2 O 2 (Fig. 2B ).
These were likely PARylated proteins that were associated with hnRNP A1 in the cells.
Next, we assessed whether these proteins could be PARylated in vitro. Of note, full-length TDP-43 (TDP-43-FL) protein expressed in bacteria was extremely insoluble. We tried several different expression vectors with different purification tags and induction temperatures, but failed to produce sufficient amount of soluble TDP-43-FL protein for the in vitro assays ( Fig. S3A-S3E ).
We thus took an alternative approach and divided TDP-43 into two truncations, TDP-43 1-274 and TDP-43 (Fig. S3A and S3F-S3G ). The purified His-tagged TDP-43 truncations as well as full-length hnRNP A1 were then subject to the in vitro PARylation reaction. Single strand DNA (ssDNA) was added to activate PARP1 in the in vitro system and the PARylation levels were examined by SDS-PAGE and immunoblotting with an anti-PAR antibody. ssDNA mimics DNA single-strand breaks that are the most common form of DNA damage in cells and can induce PARP1 activation (Kim et al., 2004; Poirier et al., 1982) , which has been frequently used in in vitro PARylation assays. Indeed, activation of PARP1 by ssDNA was evident by the dramatic increase of PARylation of PARP1 itself (Fig. 2C ). With PARP1 activation, TDP-43 1-274 and hnRNP A1 showed remarkable PARylation bands and up-shifting smears due to heterogeneity in the length of ADPr polymer attached. The purified TDP-43 274-414 protein showed a basal level of PARylation (possibly occurred during expression in bacteria), which was slightly increased in the in vitro PARlation assay. The PARylation smear of TDP-43 274-414 was much less intense than Page 7 of 39 TDP-43 1-274 , while hnRNP A1 exhibited the most robust PARylation smear in the in vitro assay (Fig. 2C ).
The human hnRNP A1 protein contains two closely-related RNA recognition motif (RRMs) in the N-terminal region and a low complexity (LC), glycine-rich domain (GRD) in the C-terminal region that includes an RGG box RNA binding domain and a M9 nuclear targeting sequence (Fig. 2D; He and Smith, 2009 ). In addition, previous mass spectrometry-based studies suggested that hnRNP A1 might contain a PARylation site at K298 and a putative PAR-binding motif (PBM) between the two RRM domains at amino acid (aa) 92-113 (Gagné et al., 2008; Martello et al., 2016) . To characterize the PARylation site(s), we generated constructs to express Flag-tag hnRNP A1 of a PARylation site mutant (K298A) or a PBM mutant (R92A-K105/106V, referred to as PBM mut thereafter) in HeLa cells. To examine the significance of PARylation, cells transfected with Flag-tagged wild-type (WT), K298A or PBM mut hnRNP A1 were treated with H 2 O 2 , and the cell lysates were examined by immunoprecipitation (IP) with anti-Flag and Western blotting with anti-PAR. Compared to WT hnRNP A1, PARylation of K298A was dramatically reduced, whereas the association with PAR was not affected in the K298A mutant, evident by the similar levels of co-immunoprecipitation (co-IP) of other PARylated proteins to WT ( Fig. 2E ). In contrast, PBM mut showed drastically decreased co-immunoprecipitation of other PARylated proteins, whereas its own PARylation was not reduced but unexpectedly increased ( Fig. 2E ). Of note, hnRNP A1 showed an up-shifting PARylation smear to a similar extent in the in vitro PARylation assay ( Fig. 2C) , indicating that the hnRNP A1 protein was capable of being massively PARylated when induced. Thus, the data suggested that binding to PAR and/or PARylated proteins via the PBM might prevent hyper-PARylation of hnRNP A1 at K298.
PARylation and PAR-binding are required for hnRNP A1 translocation to SGs
We showed that the cellular PARylation levels affected the recruitment and recovery of hnRNP A1 to and from SGs ( Fig. S1 and Fig. 1D-1F ). However, it was unclear if PARylation directly regulated the translocation of hnRNP A1 to SGs or it was an indirect effect resulted from altered Page 8 of 39 dynamics of the SGs. To address this question, we expressed the PARylation mutant K298A and PAR-binding deficient PBM mut of hnRNP A1 in HeLa cells and examined their cellular localization before and after stress by immunostaining. In the absence of stress, WT and K298A of hnRNP A1 were predominantly nuclear. PBM mut was mainly localized to the nucleus but also showed cytoplasmic foci that did not co-localize with the SG marker TIAR (Fig. 3A) . Of note, the PBM is not located within the RGG or M9 domain, the known nuclear localization sequences of hnRNP A1 ( Fig. 2D ; Siomi and Dreyfuss, 1995; Nichols et al., 2000) . Thus, it is unlikely that the PBM mut cytoplasmic foci are formed due to a defect in nuclear importing of hnRNP A1.
Next, we stressed the cells with arsenite (100 µM, 30 min) which significantly induced the formation of SGs in both WT and the two mutant hnRNP A1 K298A and PBM mut (Fig. 3A) . Thus, the overall ability of the cells to form SGs was not affected by expressing K298A or PBM mut hnRNP A1 (Fig. 3B ). In response to stress, WT hnRNPA1 showed a significant cytoplasmic translocation and co-localization with TIAR-labeled SGs (Fig. 3A and 3C ). Interestingly, K298A mutant was not recruited into SGs and remained predominantly in the nucleus ( Fig. 3A and 3C ).
In response to stress, PBM mut was recruited into TIAR-labeled SGs (Fig. 3A ), but the induction was to a less extent than WT hnRNP A1 ( Fig. 3C ). In addition, the percentage of cells with "PBM mut +/TIAR-" cytoplasmic foci showed no difference before and after stress ( Fig. 3A and 3D ), indicating that stress did not affect the formation or turnover of the PBM mut cytoplasmic foci.
Together, these data suggest that PARylation of hnRNP A1 is required for its cytoplasmic translocation, whereas binding to PAR or PARylated proteins regulates the sorting and/or delivery of hnRNP A1 to SGs.
PAR promotes phase separation of hnRNP A1
RNPs such as hnRNP A1 can phase separate in vitro, which may regulate the assembly of RNP granules and the pathological progression to amyloid aggregations in vivo (Lin et al., 2015) . The findings that hnRNP A1 was not only PARylated but also associated with PARylated proteins in vitro and in vivo (Fig. 2 ) prompted us to test whether PAR could directly regulate the LLPS of Page 9 of 39 hnRNP A1. As previously reported (Lin et al., 2015) , recombinant hnRNP A1 formed dynamic liquid droplets (LDs) in vitro, which increased in size with decreasing concentration of the salt (NaCl, 25-300 mM) and increasing concentration of hnRNP A1 (10-60 µM) ( Fig. 4A ).
Next, to determine if PAR affected the LLPS of hnRNP A1, we chose a condition at which spontaneous LLPS of hnRNP A1 barely occurred (20 µM hnRNPA1 and 25 mM NaCl, Fig. 4A ).
We added purified PAR polymers with increasing concentrations (1-7 µM) into the above in vitro demixing system, which induced the LLPS of hnRNP A1 in a dose-dependent manner (Fig. 4B ).
As a control, addition of heparin (7 µM) did not promote the LLPS of hnRNP A1 (Fig. 4C ). PAR (7 µM) alone did not alter the phase separate in vitro at the same condition ( Fig. 4D ). Thus, it is a specific effect of PAR to promote LLPS of hnRNP A1.
hnRNP A1 and TDP-43 co-phase separate in vitro and PAR promotes the co-LLPS
A recent study showed that hnRNP A2, another hnRNP family protein, could co-phase separate with TDP-43 and induced co-aggregation (Ryan et al., 2018) . Therefore, we examined whether hnRNP A1 and TDP-43 could co-phase separate in vitro and whether PAR could influence this process. As shown in Figure 5A , at the condition of 50 µM of hnRNP A1 and 100 mM of NaCl, hnRNP A1 did not phase separate spontaneously. TDP-43 1-274 (50 µM) but not BSA (50 µM) showed mild LLPS at this condition, as only a few small LDs were spotted ( Fig. 5B '-5C'). Mixing hnRNP A1 with TDP-43 1-274 (50 µM) but not BSA (50 µM) resulted in the formation of massive and much larger LDs ( Fig. 5B-5C ), suggesting that interaction with each other promoted the co-LLPS of hnRNP A1 and TDP-43 1-274 . However, although TDP-43 274-414 is more prone to phase separate even at lower concentration (20 µM; Fig. 5D '-5E'), the addition of TDP-43 274-414 did not promote phase separation of hnRNPA1 ( Fig. 5D-5E ). To further confirm the increase of LDs when hnRNP A1 and TDP-43 1-274 were mixed were indeed due to co-LLPS of two proteins rather than a single protein, we prepared fluorophore-labeled hnRNP A1 and TDP-43 1-274 . Similar to the unlabeled proteins, hnRNP A1-Alexa 647 alone did not form any LDs; TDP-43 1-274 -Alexa 555 formed a few small, green only LDs; they together formed large LDs that contained both hnRNP Page 10 of 39 A1 and TDP-43 1-274 ( Fig. 5F ). Thus, our results showed that hnRNPA1 co-phase separates with TDP-43 1-274 in vitro.
We then examined whether PAR could affect the co-LLPS of hnRNP A1 and TDP-43. To test this, we lowered the concentration of hnRNP A1 and TDP-43 1-274 to 12.5 µM each and NaCl to 50 mM, at which spontaneous co-LLPS did not occur ( Fig. 5G ). Addition of PAR (1-7 µM) but not heparin (7 µM) promoted co-LLPS of hnRNP A1 and TDP-43 1-274 in a dose-dependent manner ( Fig. 5G ). Again, we did not observe co-LLPS of hnRNP A1 with TDP-43 or any effect of PAR (7 µM) on their co-LLPS ( Fig. 5H ). Of note, no LLPS was triggered when PAR (7 µM) was added to hnRNP A1 (12.5 µM) or TDP-43 1-274 (12.5 µM) alone ( Fig. 5I ). Also, the fluorophore-labelel hnRNP A1 and TDP-43 1-274 confirmed that the LDs triggered by addition of PAR in Figure 5G contained both of the two proteins that co-phase separated in vitro. (Fig. 5J ).
PARylation modulates the interaction between hnRNP A1 and TDP-43
Next, to investigate whether hnRNP A1 interacted with TDP-43 in vivo and how PARylation regulated this process, we conducted the co-IP experiments. We found that the endogenous TDP-43 protein could be co-immunoprecipitated with transiently expressed hnRNP A1-Flag, which was consistent with the observations that TDP-43 bound to a few hnRNP family proteins (Buratti et al., 2005; D'Ambrogio et al., 2009 ). Further, we showed that the interaction between hnRNP A1 and TDP-43 depended on the presence of RNA ( Fig. S4 ). Next, we tested the effect of the PARP inhibitor Olaparib, which markedly reduced the amount of endogenous TDP-43 that were co-immunoprecipitated with hnRNP A1; on the other hand, activation of PARP1 by H 2 O 2 moderately increased the co-IP of TDP-43 with hnRNP A1 (Fig. 6A-6B ).
To understand how PARylation and PAR-binding regulated the interaction of hnRNP A1 with TDP-43, we examined the binding affinity of WT, K298A and PBM mut with TDP-43 by co-IP.
Compared to WT hnRNP A1, the PARylation site mutant K298A showed a similar capability of pull-down of TDP-43, however, the association of TDP-43 with PBM mut was dramatically reduced ( Fig. 6C-6D ). Of note, the protein level of PBM mut in the input was lower due to reduced solubility Page 11 of 39 ( Fig. S5 ). To be able to compare the co-IP efficiency with a similar input level, cells transfected with 2 times of the PBM mut expression plasmids (2xPBM mut ) were also examined. The input protein levels of PBM mut were significantly improved, however, co-IP of TDP-43 was still barely detected ( Fig. 6C-6D ). Together, these data indicate that the association of PAR or PARylated proteins via the PBM of hnRNP A1 is required for the interaction between hnRNP A1 and TDP-43.
Inhibition of PARylation reduces the cytotoxicity of hnRNP A1 and TDP-43 in motor neuron-like NSC-34 cells
We extended the study of the impact of PARylation on biochemical properties to functional readouts such as the cytotoxicity of these disease-associated RNPs. We used the mouse motor The K298A and PBM mut mutants exhibited different levels of cytotoxicity compared to WT hnRNP A1 (Fig. 7C ). The K298A mutant was more toxic than WT hnRNP A1 at both low and high concentrations of lentiviral infection. Considering that PARylation at K298A was required for cytoplasmic translocation of hnRNP A1 to SGs (Fig. 3 ), this result suggests that the inability of promptly responding to cellular stress enhances the cytotoxicity of disease-associated RNPs. PBM mut showed a similar level of cytotoxicity to WT at a low concentration of lentiviral infection.
At a higher infection concentration, the cytotoxicity of WT and K298A increased drastically, but that of PBM mut did not change much and hence became less toxic than WT and K298A at this condition ( Fig. 7C ). It was possible that the decreased binding to PARylated proteins made PBM mut and the SGs it was associated with more dynamic and less solid than those of WT hnRNP A1. This would be especially important when the proteins were expressed at high levels, Page 12 of 39 as it may reduce the chance of the SGs to develop into gel-like or solid protein aggregations that resemble the disease pathology.
As K298A and PBM mut affected the cytotoxicity of hnRNP A1 differently, we were keen to know the overall consequence of reducing PARylation levels in cells and whether it could mitigate the cytotoxicity of hnRNP A1 or TDP-43. Thus, we treated the NSC-34 cells with siRNA of PARP1 (si-PARP1). We found that downregulation of PARP1 significantly suppressed the decrease of cell viability induced by hnRNP A1 or TDP-43 OE ( Fig. 7D-7F ). Furthermore, as an attempt to testing small-molecule for treating ALS, we examined the PARP inhibitor Olaparib. We tested different doses and found that 5 µM of Olaparib did not reduce the viability of NSC-34 cells but showed a remarkable suppression of TDP-43 OE-mediated cytotoxicity ( Fig. 7G ). Thus, both genetic and pharmacological inhibition of PARP significantly suppressed the cytotoxicity of ALS-associated RNPs in MN-like NSC-34 cells.
Downregulation of Parp suppresses TDP-43-mediated neurodegeneration in a Drosophila

model of ALS
Finally, we validated these findings in an in vivo model of ALS using transgenic flies expressing human TDP-43 (hTDP-43). hTDP-43 OE in the fly photoreceptor cells (GMR driver) caused age-dependent eye degeneration, which was drastically suppressed by transgenic downregulation of fly Parp (RNAi-Parp) compared to RNAi-Ctrl ( Fig. 8A-8B ). We examined the KD efficiency of RNAi-Parp by quantitative real-time PCR (qPCR) assay and the mRNA level of Parp was reduced to below 40% of the RNAi-ctrl group (Fig. S7A ). Also, we showed that the reduction of Parp did not affect the protein levels or solubility of hTDP-43 ( Fig. S7B-S7C) , confirming that the suppression by RNAi-Parp was not due to a reduction of transgenically expressed hTDP-43 protein in the system. Furthermore, we performed the climbing and lifespan assays to evaluate the behavioral consequences, which might represent more closely to the disease-relevant symptoms in ALS. We induced hTDP-43 OE in adult fly neurons using an elavGS driver and added RU486 to the fly food (80 µg/ml) starting from day one of the adulthood.
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It caused an age-dependent decline of the climbing capability and a significant shortening of the lifespan, both of which could be suppressed by RNAi-Parp in the fly neurons ( Fig. 8C-8D ).
Together, these data indicate that PARP can modify TDP-43-mediated neurodegeneration in vivo.
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DISCUSSION
PARylation regulates SG dynamics and phase separation of RNPs
In this study, we reveal that decrease of the cellular PARylation levels suppresses the formation of SGs and the recruitment of ALS-related RNPs such as TDP-43 and hnRNPA1 to SGs, while increase of PARylation levels delays the disassembly of SGs and the recovery of the RNPs.
Interestingly, the function of PARylation appears to be specifically enriched in regulation of RNA/DNA-binding proteins and the associated complexes. For example, PARylation is involved in the regulation of the mitotic spindle (Chang et al., 2004) , Cajal bodies (Kotova et al., 2009 ), DNA damage repair (Ahel et al., 2009) , and microRNA-mediated translational repression (Leung et al., 2011) . Because of their essential role in RNA processing and homeostasis (Dreyfuss et al., 1993; Lee et al., 2012) , dysregulation of RNP granules contributes to the pathogenesis of neurodegenerative diseases (Anderson and Kedersha, 2009; Buchan and Parker, 2009; Zhang et al., 2018) . This is at least in part because many of the RNPs contain intrinsically disordered LC domains that can undergo spontaneous self-assembly via LLPS to generate higher-order structures such as solidified LDs, and irreversible amyloid fibrils. We find that adding PAR to the demixing system dramatically promotes the LLPS of hnRNP A1 as well as the co-LLPS of hnRNP A1 with TDP-43. Consistently, during manuscript preparation of this study, an independent study recently published online reporting that the liquid demixing of TDP-43 could be affected by PAR (McGurk et al., 2018) . Thus, the reversible modification of PARylation may serve as an important regulator of the dynamics of RNP granules, which in case of lasting stimuli or excessive PARylation, pathological irreversible RNP aggregates may form (Fig. 8E ).
The dual regulations of hnRNP A1 by PARylation and PAR-binding
hnRNP A1 can form protein complexes with TDP-43 and other RNPs to regulate RNA processing (Buratti et al., 2005; Mohagheghi et al., 2016) . Indeed, we find that hnRNP A1 and TDP-43 can co-phase separate in vitro and PARylation strongly regulates their interaction in vitro and in cells. The hnRNP family proteins constitute an important component of the SGs and are Page 15 of 39 highly regulated at molecular and cellular levels. For example, pathogenic mutations in the GRD of hnRNP A1 accelerate its recruitment to SGs and the fibrillization (Kim et al., 2013) , while methylation of hnRNP A2 in the RGG domain suppresses the phase separation of hnRNP A2 (Ryan et al., 2018) .
In this study, we show that PARylation regulates the LLPS of hnRNP A1 in vitro and the translocation of hnRNP A1 to SGs in vivo. We further reveal that hnRNP A1 contains a PARylation site at K298 that is in the GRD as well as a PBM that resides in between the two RRMs. K298 localizes at the C-terminus of the M9 domain, a non-classical nuclear localization sequence of hnRNP A1. Of note, K298 is not within the M9 core sequence (SNFGPMKGGNFGGRSSGPY) that is crucial for the nuclear import and binding to transportin (Iijima et al., 2006) . Indeed, the PARylation deficient K298A mutant shows no defect in nuclear importing. Instead, it does not translocate to the cytoplasm in response to stress and exhibits the strongest toxicity among the three hnRNP A1 species tested in this study (see Fig. 7 ). These data implicate the PARylation at K298 as an important mechanism for hnRNP A1 to sense stress and/or serve as a nuclear exporting signal.
The PAR-binding deficient PBM mut of hnRNP A1 can respond to stress and translocate to SGs, likely because the signaling mechanims by PARylatino at K298 is intact. However, the SG recruitment of PBM mut is less effective than WT and a portion of PBM mut forms mis-localized cytoplasmic foci that do not co-localize to SGs. Of note, PBM mut shows hyper-PARylation in the in vitro assay (see Fig. 2C ), possibly at K298 of hnRNP A1, which may result in abnormal activation of the nuclear exporting of PBM mut . In the meanwhile, since PBM mut shows a greatly reduced capacity to pull down PARylated proteins, we speculate that the association with PAR or PARylated proteins ensures the proper transport and anchoring of hnRNP A1 with SGs. Despite of forming cytoplasmic foci, PBM mut is not more toxic than WT hnRNP A1. Instead, PBM mut is less toxic especially when expressed at high levels (see Fig. 7 ). It is possibly because the reduced association of PBM mut with SGs makes the granules less prone to develop into pathogenic aggregates. And this effect may be particular important when the protein is at high abundance as Page 16 of 39 LLPS of hnRNP A1 occurs with increasing concentrations and PAR promotes this process in a dose-dependent manner. It is worth noting that this is unlike the PBM mutant of TDP-43, which is thought to be more toxic because it could not be recruited to SGs and formed hyper-phosphorylated cytoplasmic foci (McGurk et al., 2018) . Nevertheless, downregulation of PARylation levels reduces the cytotoxicity of hnRNP A1 and TDP-43 in both cases (see Fig. 7 ), which suggests that, under disease conditions, reduction of PAR-mediated association of RNPs and restore of the dynamics of RNP granules may be beneficial.
Potential therapeutic values of PARP inhibitors for neurodegenerative diseases
Small-molecule inhibitors of PARP enzymes have received increasing interests since the initial discovery of them in killing BRCA1/2-mutant cancer cells. While the involvement of PARP in DNA damage repair has heralded the development of PARP inhibitors in cancer biology and therapy (Davar et al., 2012) , the functions of PARP are beyond DNA repair and oncology (Bai, 2015) . For example, the neuroprotective effects of PARP inhibitors have been reported in Hungtinton's disease, cerebral ischemia and axonal regeneration (Cardinale et al., 2015; Egi et al., 2011; Teng et al., 2016; Brochier et al., 2015) . In this study, we show that Olaparib, the PARP inhibitor approved by FDA for treating ovarian cancer and breast cancer, can significantly reduce the neurotoxicity of hnRNP A1 and TDP-43 in a motor neuron-like cell line, likely due to the pivotal role of PARP in regulating the protein-protein interaction and the dynamics of the disease-associated, aggregation-prone RNP granules. Therefore, we propose Olaparib as a candidate for developing ALS drugs, and further animal and clinical studies are needed to evaluate the potential therapeutic values of Olaparib and other PARP inhibitors to treat ALS and other RNP-related diseases.
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MATERIALS AND METHODS
Plasmids and constructs
To generate pCAG-TDP-43-HA, pCMV-TDP-43-3xFlag and pBID-UASC-TDP-43 plasmids, human TDP-43 DNA was amplified from a TDP-43-Myc plasmid (Jiang et al., 2013) by PCR using the primers specified below. The desired PCR products were subcloned into a pCAG vector (Chen et al., 2014) 
Stress granule induction
HeLa cells grown on coverslips in a 12-well plate were treated with 100 µM of NaAsO 2 or PBS for 30 min before they were fixed with 4% paraformaldehyde. For recovery, the medium containing NaAsO2 was removed and the cells were incubated in fresh medium for indicated time before fixation. Formation of stress granules was evaluated by subsequent immunocytochemistry assays.
Immunocytochemistry and confocal imaging
After transfection and drug treatments, cells grown on the cover slips in 24-well plate were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature, permeabilized in 0.5% Triton X-100 in PBS for 10 min, and blocked with 3% goat serum in PBST (PBS + 0.1% Triton X-100)
for 30 min at room temperature. The primary and secondary antibodies in the blocking buffer Page 20 of 39 were then incubated at 4°C overnight or at room temperature for 1 h. After 3 washes with PBST, cells were mounted on glass slides using Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories). Fluorescent images were taken with Leica TCS SP8 confocal microscopy system using a 100X oil objective (NA=1.4). Images were processed and assembled into figures using LAS X (Leica) and Adobe Photoshop CS6.
Protein extraction and Western blotting
Total protein was extracted from cells in 2% SDS extraction buffer (50 mM Tris pH 6.8, 2% SDS, 1% mercaptoethanol, 12.5% glycerol and 0.04% bromophenol blue) containing the protease inhibitor cocktail (Roche, 04693132001), 20 µM Olaparib (Selleck, S1060) and 8 µM ADP-HPD (Millopore, 118415) . To separation of soluble and insoluble proteins, cells or fly heads were lysed on ice in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitors. After sonication, the homogenates were centrifuged at 13,000 x g for 10-20 min at 4°C. The supernatant was used as the soluble fraction and the pellets containing insoluble fractions were dissolved in a 9 M urea buffer (9 M urea, 50 mM Tris buffer, pH 8.0) after wash.
Proteins were separated by 10% Bis-Tris SDS-PAGE (Invitrogen), immunoblotted with the primary and secondary antibodies. Detection was performed using the High-sig ECL Western Blotting Substrate (Tanon). Images were captured using an Amersham Imager 600 (GE Healthcare) and densitometry was measured using ImageQuant TL Software (GE Healthcare).
The contrast and brightness were optimized equally using Adobe Photoshop CS6 (Adobe Systems Inc.). All experiments were normalized to GAPDH or tubulin as indicated in the figures.
Co-immunoprecipitation
HeLa cells were lysed in IP buffer (25 mM Tris•HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol) containing protease inhibitor cocktails, 20 µM Olaparib and 8 µM ADP-HPD.
To test if the interaction between hnRNP A1 and TDP-43 was RNA-dependent, cell lysates were Page 21 of 39 treated with 100 mg/ml of RNase A for 30 min (Qiagen), and then incubated with mouse anti-Flag or rabbit anti-HA antibody on a rotary shaker at 4°C overnight. Mouse or rabbit IgG (Santa Cruz, sc-2025 or sc2027) was used as a control for the pull-down specificity. Anti-FLAG® M2 Affinity Gel (Sigma, A2220) or Dynabeads® Protein G beads (Novex) were then added and incubated at room temperature for 2 h. The gel or beads were then collected according to the manufacture's instruction and eluted in the 2xLDS sample buffer (Invitrogen) before the subsequent Western blotting assay.
Antibodies
The following antibodies were used for Western blotting, immunoprecipitation and (buffer A with 1 M NaCl). Then, hnRNPA1 protein were further purified by Superdex 75 16/600 column (GE Healthcare) in a buffer containing 50 mM Tris-HCl pH 7.5, 500 mM NaCl and 2 mM DTT. Fractions containing hnRNPA1 monomers were collected and concentrated for following studies.
All the purified proteins were confirmed by Coomassie brilliant blue staining and Western blotting.
In vitro PARylation assay
In vitro PARylation assay was performed according to the protocol adapted from (Slade et al., 2011) . Briefly, substrate proteins were incubated with PARP1 (Sino Biological) in the presence of NAD in reaction buffer (50 mM Tris-Hcl, pH 7.4, 2 mM MgCl 2 ) with or without 2.5 µg of ssDNA (Sigma) at 37 °C for 30 min. The reactions were stopped by adding 20 µM Olaparib and the products were examined by SDS-PAGE and Western blotting.
In vitro phase separation
For the in vitro demixing experiments, purified hnRNP A1, PAR polymers (Trevigen, 4336-100-01) and NaCl at indicated concentrations were mixed into a phase separation buffer (50 mM Tris-HCl, pH 7.5, 10% (w/v) PEG (Sigma) and 2 mM DTT) and incubated for 3 min at room temperature. For co-LLPS, hnRNP A1 protein were incubated with TDP-43 in a buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl and 2 mM DTT. 5 µL of each samples was pipetted onto a coverslip and imaged using a Leica microscope with differential interference contrast (DIC).
Fluorophore-labeled of hnRNP A1 and TDP-43
Purified TDP-43 1-274 and hnRNP A1 proteins in storage buffer were desalted in a reaction buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl and 4 mM Tris (2-Carboxyethyl) Phosphine (TCEP)
Page 24 of 39 (Invitrogen, T2556) using a desalting column (GE Healthcare, USA) to remove DTT. The proteins were then incubated with 5-fold AlexaFluor-555 C2-malemide (invitrogen, A20346) for TDP-43 1-274 or AlexaFluor-647 C2-malemide (invitrogen, A20347) for hnRNPA1 at room temperature for 2 h to conjugate the malemide derivative dye to a thiol group of Cys on the target proteins. The labeled proteins were further purified by Superdex 200 10/300 columns (GE Healthcare, USA) in a buffer containing 50 mM Tris-HCl, pH 7.5, 500 mM NaCl. Unlabeled proteins were mixed with one percent of labeled proteins for subsequent in vitro phase separation and confocal imaging.
Lentivirus production and infection
293T cells were co-transfected with psPAX2, pMD2.G and pCDH-CMV-MCS-EF1-Puro plasmids of Flag, TDP-43-Flag, WT and the mutant hnRNP A1-HA (K298A and PBM mut ), using the PolyJet™ reagent. Cell culture medium was collected and filtered through a 0.45 µm syringe filter (Millipore, SLHV033RB) at 48 h after transfection. The lentivirus was then concentrated using Lenti-X™ Concentrator (Clontech, PT4421-2). The 20-fold concentrated medium containing the desired lentivirus was used to infect NSC-34 cells in the subsequent experiments. 
Cell viability assay
TUNEL staining
Page 25 of 39 TUNEL staining assay was performed using the TMR red in situ Cell Death Detection Kit (Sigma-Aldrich) according to the manufacturer's instruction. The transfected NSC-34 cells grown on coverslips in a 24-well plate were fixed with 4% paraformaldehyde for 15 min and permeabilized with PBST (1xPBS + 0.5% Triton X-100) for 10 min at room temperature, followed by incubation with 18 µl labeling solution plus 2 µl enzyme solution at 37 °C for 1 h. Cell were mounted on glass slides using Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories) and imaged using the Leica TCS SP8 confocal microscopy system.
Drosophila strains
The following strains were obtained from the Bloomington Drosophila Stock Center (BDSC):
RNAi-Parp (#57265), elavGS (#43642), RNAi-mCherry (#35785, a control for in vivo RNAi knockdown). The transgenic fly strain of UAS-TDP-43 was generated by ΦC31
integrase-mediated, site-specific integration into the fly genome, which allowed uniform transgene expression across different lines. The attP landing site stock used in this study was UAS-phi2b2a;VK5 (75B1) and a transgenic pBID-UASC-Luciferase (UAS-Luc) fly strain generated using the same method and the same landing site (Cao et al., 2017) was used as a control in this study. All flies were raised on standard cornmeal media and maintained at 25 °C and 60% relative humidity. or accidental death were excluded from the final analysis. The median lifespan was calculated as the mean of the medians of each vial in a group, whereas the "50% survival" shown on the survival curves is derived from compilation of all vials of a group. For adult-onset, neuronal expression of the RNAi transgenes using the elav-GS driver (Osterwalder et al., 2001) , flies were raised at 25 °C and 60% relative humidity on regular fly food supplemented with 80 µg/ml RU486 (TCI).
Climbing ability and Lifespan assays
Statistical analysis
Unless otherwise noted, statistical significance in this study is determined by unpaired, two-tailed 
